CirculationReview
19 Nov 2024
Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available.
However, progress has been modest to date with few precision tools available for clinicians.
Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance.
Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping.
Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit.
Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.
Dr de Lemos reports grant support from Abbott Diagnostics, consulting fees from Quidel Cardiovascular, Inc., honoraria for participation in end point committees from Beckman Coulter and Siemen’s Health Care Diagnostics, and fees for participation in Data Monitoring Committees from Astra Zeneca, Novo Nordisc, Eli Lilly, Merck, Regeneron, Amgen, and Verve Therapeutics. Dr de Lemos has been named a co-owner on a patent awarded to the University of Maryland (US Patent Application Number: 15/309,754) entitled: “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr Shah reports consulting fees from Philips Ultrasound and Janssen and research funds from Novartis through Brigham and Women’s Hospital. Dr Berry reports grant support from the NIH, Roche Diagnostics, and Abbott Diagnostics and consulting fees from Roche Diagnostics, Astra Zeneca, and the Cooper Institute.
More resources:
Share: